SB 355, titled the FDA Modernization Act 3.0, directs the Secretary of Health and Human Services, acting through the FDA Commissioner, to issue an interim final rule within one year to conform FDA regulations to prior statutory changes made in the Consolidated Appropriations Act, 2023. The bill requires the FDA to replace references to “animal” tests, data, studies, models, and research in specified regulations with the broader term “nonclinical” tests, data, studies, models, and research, and to add the statutory definition of “nonclinical test” into several FDA regulatory provisions.
The bill also makes a technical amendment to the Federal Food, Drug, and Cosmetic Act to renumber an existing subsection related to clinical trial diversity action plans. In practical terms, the measure is a regulatory cleanup and implementation bill: it does not create a new testing regime, but it updates FDA rules to align with current law and terminology governing drug and biologics development, nonclinical evidence, and related submission requirements.
Impact
The bill would affect the Federal Food, Drug, and Cosmetic Act and multiple FDA regulations in Title 21 of the Code of Federal Regulations, including provisions governing investigational new drug applications, new drug applications, biologics, and related regulatory submissions. It would require the FDA to revise regulatory text to reflect the statutory shift from animal-specific language to nonclinical testing terminology and to ensure consistency across affected sections. The technical amendment would also renumber a subsection in section 505 of the FDCA, which may affect cross-references but does not appear to change substantive policy.
Sentiment
The available context suggests generally favorable or at least noncontroversial sentiment around the bill, as reflected by its passage in the Senate and the absence of recorded committee debate or votes in the provided materials. The measure appears to be viewed as a technical implementation and modernization bill rather than a major policy change, which typically draws limited opposition. The lack of transcripts or recorded dissent in the supplied context indicates no documented organized resistance in the materials provided.
Contention
The main point of potential contention is the shift in regulatory language from “animal” testing to “nonclinical” testing. Supporters are likely to view this as a modernization effort that better reflects alternative testing methods and aligns FDA regulations with existing statutory changes, while critics could be concerned about whether the terminology change could be interpreted as weakening expectations for preclinical safety evidence or creating ambiguity in regulatory standards. A secondary issue is the use of an interim final rule that becomes immediately effective without a separate good-cause showing, which may raise procedural concerns for those who prefer fuller notice-and-comment rulemaking. However, no specific opposition is documented in the provided context.